Navigation Links
TNF Blockers May Help Some With Rheumatoid Arthritis
Date:8/6/2009

If standard treatment fails, more intensive therapy works well, study finds

THURSDAY, Aug. 6 (HealthDay News) -- Patients with early rheumatoid arthritis (RA) who respond poorly to standard treatment with methotrexate may benefit from additional treatment with tumor necrosis factor (TNF) blockers, a Swedish study suggests.

Previous research has shown that 20 percent to 40 percent of patients have a good response to methotrexate therapy and don't need more intensive combination treatment.

This new study included 487 patients with early RA (less than one year's duration) who were initially treated with methotrexate. After three to four months, the 258 patients with an inadequate response to methotrexate were randomly assigned to receive either the TNF blocker infliximib (Remicade) or the conventional disease-modifying antirheumatic drugs, sulfasalazine and hydroxychloroquine.

After 12 months, 39 percent of patients given infliximib achieved a good response, compared with 25 percent of patients given sulfasalazine and hydroxychloroquine.

"We believe that by treating all patients with methotrexate for 3 to 4 months, we screened out a sizeable proportion [30 percent in this trial] who would have been overtreated if aggressive combination therapy was used for all, an approach that could have increased the risk of side effects and potentially entailed high costs," wrote the researchers from the Karolinska University Hospital and the Karolinska Institute.

A short period of treatment with methotrexate alone, followed by the addition of a TNF blocker only in patients who have an inadequate response to methotrexate, is the best treatment option for patients with early RA, they concluded.

The study appears in this week's edition of The Lancet.

In related news, the U.S. Food and Drug Administration on Tuesday ordered that TNF blockers carry an updated "black box" label to warn doctors and patients that the drugs may increase the risk of cancer in children and adolescents.

More information

The Arthritis Foundation has more about rheumatoid arthritis.



-- Robert Preidt



SOURCE: The Lancet, news release, Aug. 6, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers
2. Beta-Blockers Tied to Higher Cataract Risk
3. Questions Continue About Using Beta Blockers Before Surgery
4. Beta Blockers Help Hospitalized Heart Failure Patients
5. Beta Blockers Raise Stroke, Death Risk After Surgery
6. Women are treated less frequently than men with statins, aspirin and beta-blockers
7. Scripps scientists find calcium channel blockers help normalize lysosomal storage disease cells
8. Decision Resources Updated Rheumatoid Arthritis Report Now Includes Forecast for Rigel Pharmaceuticals Fostamatinib Disodium
9. Lexicon Initiates Phase 2 Clinical Trial of LX2931 in Patients With Rheumatoid Arthritis
10. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi3 Clinical Trial of R788 in Rheumatoid Arthritis
11. For Treatment of Rheumatoid Arthritis, Surveyed Rheumatologists and Patients Differ In Their Perception of Bristol-Myers Squibbs Orencia
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
TNF Blockers May Help Some With Rheumatoid Arthritis
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/26/2016)... ... , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... a whole new perspective by using the title layers in ProSlice Levels to ... ProSlice Levels contains over 30 Different presets to choose from. FCPX users ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets has ... Market Analysis 2016 - Forecast to 2022" report to ... report contains up to date financial data derived from varied ... major trends with potential impact on the market during the ... segmentation which comprises of sub markets, regional and country level ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
(Date:6/23/2016)... June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations ... Latin America . ... ... ... ...
Breaking Medicine Technology: